On December 30, 2020, a demande de brevet for a pharmaceutique composition for treating TRPV1 activation-mediated diseases was completed in the États-Unis, bringing the total number of completed applications to three — Korea, the U.S., and PCT. Depending on registration status, l'entreprise plans to extend the patent to China, Europe, Japan, and other regions.
This patent covers the potential of TRPV1 in divers pain conditions and allows for expansion into protein thérapeutiques, gene therapy, and other modalities. It devrait hold value as a use patent for divers pain conditions upon registration.